drugset / Trial / NCT04397289

Anticoagulation Therapy After Splenectomy in Cirrhosis Patient

NCT04397289

Phase 1/2 Completed 70 enrolled First Affiliated Hospital Xi'an Jiaotong University
RandomizedParallel-groupSingle-blindPrevention

Summary

1\. Inclusion and Exclusion Criteria Inclusion criteria: Inpatients who received laparotomy or laparoscopic splenectomy according to clinical, B-ultrasound scan, CT or MRI diagnosis of cirrhosis and portal hypertension. Exclusion criteria: 1. ) Portal vein system thrombosis (PVST) found by preoperative color Doppler ultrasound or MRI examination; 2. ) Liver cirrhosis complicated with liver tumor; 3. ) Liver cirrhosis complicated with blood system diseases; 4. ) Patients who have not signed the informed consent form. 2\. Research subgroup According to the order of the patients, the following groups are entered in turn, and the cycle is repeated. 1. ) Heparin group 2. ) Rivaroxaban group 3. ) Control group.

Timeline

Start
2018-02-12
Primary completion
2021-03-31
Completion
2021-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Heparin Other / unclassified 5000 iu Subcutaneous
Subject Rivaroxaban Other / unclassified 10 mg Oral